Egypt Negotiates $300 Price For Gilead's Hep C Drug
This article was originally published in PharmAsia News
Executive Summary
Egypt, which has the world's highest rate of hepatitis C infections, said it has negotiated a shipment of a second batch of Gilead's Sovaldi (sofosbuvir) for $300 a treatment regimen.